DR. HÖNLE AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.9 EUR | 0.00% |
|
-0.50% | +13.71% |
| Feb. 26 | Dr. Hönle AG Reports Earnings Results for the First Quarter Ended December 31, 2023 | CI |
| Jan. 25 | Dr. Hönle AG Reports Earnings Results for the Full Year Ended September 30, 2023 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is in debt and has limited leeway for investment
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 41.46 times its estimated earnings per share for the ongoing year.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Industrial Machinery & Equipment
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +13.71% | 129M | C- | ||
| +11.73% | 82.35B | A- | ||
| +20.17% | 71.09B | B | ||
| +20.89% | 37.73B | B- | ||
| +15.77% | 32.01B | A | ||
| +9.19% | 27.2B | B- | ||
| +3.18% | 26.74B | C+ | ||
| +4.22% | 26B | B+ | ||
| +13.49% | 25.5B | B+ | ||
| +17.14% | 24.76B | B |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- HNL Stock
- Ratings Dr. Hönle AG
